Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)
Close on Nov 17, 2026Market cap $43.60MP/E –Yield –
Xilio Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Xilio Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $66.83M, up 54.7% year over year. For fiscal 2025 it was $56.04M, up 36.0% from the year before. The highest annual figure on record is $59.20M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.04M | +36.0% |
| FY2024 | Dec 31, 2024 | $41.21M | -21.0% |
| FY2023 | Dec 31, 2023 | $52.14M | -11.9% |
| FY2022 | Dec 31, 2022 | $59.20M | +15.7% |
| FY2021 | Dec 31, 2021 | $51.19M | +16.6% |
| FY2020 | Dec 31, 2020 | $43.91M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.56M | -5.0% |
| Q1 FY2026 | Mar 31, 2026 | $19.83M | +139.9% |
| Q4 FY2025 | Dec 31, 2025 | $18.12M | +105.1% |
| Q3 FY2025 | Sep 30, 2025 | $14.32M | +33.1% |
| Q2 FY2025 | Jun 30, 2025 | $15.33M | +36.7% |
| Q1 FY2025 | Mar 31, 2025 | $8.27M | -20.5% |
| Q4 FY2024 | Dec 31, 2024 | $8.84M | -24.7% |
| Q3 FY2024 | Sep 30, 2024 | $10.76M | -2.6% |
| Q2 FY2024 | Jun 30, 2024 | $11.22M | -15.1% |
| Q1 FY2024 | Mar 31, 2024 | $10.40M | -35.5% |
| Q4 FY2023 | Dec 31, 2023 | $11.74M | -21.7% |
| Q3 FY2023 | Sep 30, 2023 | $11.05M | -15.2% |
| Q2 FY2023 | Jun 30, 2023 | $13.22M | -18.6% |
| Q1 FY2023 | Mar 31, 2023 | $16.13M | +8.1% |
| Q4 FY2022 | Dec 31, 2022 | $15.00M | +32.1% |
| Q3 FY2022 | Sep 30, 2022 | $13.04M | +24.5% |
| Q2 FY2022 | Jun 30, 2022 | $16.25M | -8.4% |
| Q1 FY2022 | Mar 31, 2022 | $14.92M | +28.4% |
| Q4 FY2021 | Dec 31, 2021 | $11.35M | -35.7% |
| Q3 FY2021 | Sep 30, 2021 | $10.47M | -8.6% |
| Q2 FY2021 | Jun 30, 2021 | $17.75M | – |
| Q1 FY2021 | Mar 31, 2021 | $11.62M | – |
| Q4 FY2020 | Dec 31, 2020 | $17.67M | – |
| Q3 FY2020 | Sep 30, 2020 | $11.46M | – |
See a number that looks wrong?